01 Automated Insulin Delivery Systems Automated insulin delivery systems are becoming more relevant as people with type 1 diabetes seek better glucose control with less manual insulin adjustment. The transition toward hybrid closed-loop systems connects continuous glucose monitoring with insulin pumps and algorithms, with a real-world study of 2,284 users in Greece reporting average time in range of 75.4%. This shift supports wider use of automated insulin delivery across European diabetes care.
02 Mobile App Integration with Diabetes Devices Mobile app integration is improving diabetes management by connecting glucose sensors, insulin pumps, and digital health platforms through smartphone-based interfaces. The transition toward app-connected devices allows patients and clinicians to review glucose data and treatment information remotely, while a European real-world study of a hybrid closed-loop app with a continuous glucose monitor and insulin pump reported 72.6% average time in range among 100 users. This integration supports more continuous monitoring and personalized diabetes management.
01 Need for Better Glycemic Monitoring in Older Adults and Availability of Wearable Glucose Monitoring Devices Drive Market Older adults with diabetes often require regular glucose monitoring to support medication management and reduce the risk of glucose fluctuations.Easy-to-use monitoring devices can support patients with limited dexterity, vision, or mobility and reduce the burden of frequent finger-prick testing.Healthcare providers therefore have greater scope to use accessible glucose-monitoring devices for elderly patients in hospitals and home-care settings.For example, continuous glucose monitors can provide repeated glucose readings without requiring a finger-stick test for every measurement.Broader use of age-friendly monitoring solutions supports device adoption across Europe.Wearable glucose monitors provide continuous or frequent glucose readings through sensors placed on or under the skin.Sensor-based monitoring gives patients and healthcare professionals more information on glucose patterns than occasional blood glucose checks.The availability of products such as Abbott’s FreeStyle Libre and Dexcom’s continuous glucose monitoring systems expands the range of monitoring options across European healthcare settings.Home-based and outpatient diabetes care can benefit from these devices because patients can monitor glucose levels during daily activities.Wider availability of wearable systems supports the European supply of advanced diabetes-monitoring devices.
01 Stringent Regulatory Requirements and Patient Concerns About Device Accuracy and Safety Restrain Market Expansion Stringent regulatory requirements involve extensive clinical evidence, safety testing, quality checks, and documentation before diabetes devices reach the European market.These requirements increase development costs and extend approval timelines, particularly for innovative monitoring and delivery devices. This regulatory burden can delay product launches and limit the pace of new-device adoption.Patient concerns about device accuracy and safety can reduce confidence in glucose monitors, insulin delivery systems, and other diabetes technologies. Concerns about inaccurate readings, device failures, or incorrect insulin delivery can make some patients reluctant to adopt newer devices. This hesitation can limit device uptake and slow market expansion.
01 Expansion of Diabetes Devices in Home Healthcare and Diabetes Device Training and Support Services Offers Growth Opportunities Home-care providers, diabetes device manufacturers, and healthcare organizations are key beneficiaries, as home-based diabetes management reduces dependence on frequent clinic visits. Home-use devices create revenue through direct device sales, monitoring services, patient-support packages, and long-term care programs. Companies such as Abbott and Dexcom have products designed for diabetes management outside traditional clinical settings.
01 Device Interoperability Gaps and Slow Adoption by Healthcare Professionals Hinders Growth Differences in data formats and connectivity between glucose monitors, insulin pumps, apps, and clinical systems can make integration difficult. This can slow adoption of connected diabetes devices and increase development requirements for manufacturersLimited time, training, infrastructure, and workload pressures can make healthcare professionals slower to incorporate digital diabetes technologies into routine care. WHO identified these factors as barriers to digital-health adoption across Europe.
July 2026 Insulet commercially launched the Omnipod 5 Automated Insulin Delivery System and Omnipod Discover in Spain, expanding access to its tubeless insulin delivery technology and data management platform in the European market.
May 2026 QIAGEN announced plans to launch a fully automated Sample-to-Insight workflow for QuantiFERON testing in partnership with Inpeco, while expanding automation capabilities that support high-throughput diagnostic laboratories across Europe. (Excluded if focusing strictly on diabetes devices; include only if your scope covers broader diagnostic device infrastructure.)
May 2025 Medtronic announced its intention to separate its Diabetes business into an independent publicly traded company, creating a dedicated diabetes technology company focused on accelerating innovation in insulin pumps, continuous glucose monitoring integration, and automated insulin delivery systems.
May 2025 Abbott and Medtronic expanded the rollout of integrated continuous glucose monitoring compatibility across European markets, strengthening interoperability between Abbott's FreeStyle Libre technology and Medtronic's automated insulin delivery ecosystem.